Valuation: Nectar Lifesciences Limited

Market Cap 1.81B 18.89M 16.32M 15.33M 13.95M 26.22M 26.65M 180M 70.25M 905M 70.94M 69.4M 3.01B P/E 2024
137x
P/E 2025 -4.53x
Enterprise Value 7.43B 77.69M 67.1M 63.06M 57.35M 108M 110M 739M 289M 3.72B 292M 285M 12.36B EV / Sales 2024
0.77x
EV / Sales 2025 0.64x
Free-Float
44.34%
Yield 2024 *
-
Yield 2025 -
08-14 Nectar Lifesciences Limited Announces Board and Committee Changes, Effective August 14, 2026 CI
08-14 Nectar Lifesciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
08-06 Nectar Lifesciences Limited Announces Resignation of Dr. Surulichamy Senthilkumar from Non-Executive Non-Independent Director, Effective August 06, 2026 CI
07-11 Nectar Lifesciences Limited Announces Change in Registered Office Address CI
05-30 Nectar Lifesciences Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
03-05 Nectar Lifesciences Limited completed the acquisition of Avensis Exports Private Limited. CI
03-02 Nectar Lifesciences to acquire 100% paid-up equity share capital of Avensis Exports RE
03-01 Nectar Lifesciences Limited agreed to acquire Avensis Exports Private Limited for INR 2.5 million. CI
01-23 Nectar Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
01-15 Tranche Update on Nectar Lifesciences Limited's Equity Buyback Plan announced on December 3, 2025. CI
01-05 Nectar Lifesciences Limited's Equity Buyback announced on May 6, 2023, has closed with 30,000,000 shares, representing 13.38% for INR 810 million. CI
12-19 Capnest Health Care Private Limited entered into Business Transfer agreement to acquire Empty Hard Gelatin Capsule unit at Bhatoli from Nectar Lifesciences Limited for approximately INR 200 million. CI
12-03 Nectar Lifesciences approves buyback of shares valued at 810 million rupees RE
1 day-3.00%
1 week+3.97%
Current month+3.97%
1 month-1.70%
3 months-13.73%
6 months-17.91%
Current year-43.33%
1 week 10.11
Extreme 10.11
11.65
1 month 9.98
Extreme 9.98
11.65
Current year 9.3
Extreme 9.3
20.9
1 year 9.3
Extreme 9.3
22.4
3 years 9.3
Extreme 9.3
56.5
5 years 9.3
Extreme 9.3
56.5
10 years 7.1
Extreme 7.1
56.5
Manager TitleAgeSince
Director of Finance/CFO 68 2022-11-13
Compliance Officer - 2025-03-31
Director TitleAgeSince
Chairman 66 1995-06-26
Director/Board Member 69 2019-02-10
Director/Board Member 75 2021-09-20
Date Insider Type Main position Quantity % Market Cap.
12/19/24 Buy 400,000 0.1784%
Change 5-day change 1-year change 3-year change Capi.($)
-3.00%+3.97%-24.24%-55.47% 22.35M
-0.10%-0.77%+17.58%+70.16% 48.43B
-3.26%-5.31%+53.19%+117.23% 39.72B
-0.60%-0.94%-7.29%+17.35% 12.25B
-2.75%+1.88%+14.81%+76.92% 11.84B
-0.19%-0.38%+30.40%+135.91% 9.06B
+1.56%+5.52%+23.46%+39.78% 7.57B
+0.52%+2.08%+40.75%-12.45% 7.18B
-0.07%+1.72%+13.39%+190.65% 6.84B
-2.51%-3.14%-27.46%+24.20% 5.77B
Average -1.04%+2.15%+13.46%+60.43% 14.87B
Weighted average by Cap. -1.18%+1.03%+25.08%+81.14%

Financials

2024 2025
Net sales 16.85B 176M 152M 143M 130M 244M 249M 1.68B 655M 8.44B 661M 647M 28.03B 16.7B 175M 151M 142M 129M 242M 246M 1.66B 650M 8.36B 656M 642M 27.8B
Net income 49.95M 522K 451K 424K 386K 725K 737K 4.97M 1.94M 25.01M 1.96M 1.92M 83.12M -1.14B -11.89M -10.27M -9.65M -8.78M -16.5M -16.77M -113M -44.2M -569M -44.64M -43.67M -1.89B
Net Debt 6.15B 64.34M 55.57M 52.22M 47.49M 89.29M 90.76M 612M 239M 3.08B 242M 236M 10.24B 5.62B 58.8M 50.79M 47.72M 43.4M 81.6M 82.94M 559M 219M 2.82B 221M 216M 9.36B
Logo Nectar Lifesciences Limited
Nectar Lifesciences Limited is an India-based pharmaceutical company. The Company's business areas include active pharmaceutical ingredients (APIs) and intermediates, formulations/finished dosage formulations (FDF), menthol and mint derivatives, and empty hard gelatin capsules. The Company is engaged in the manufacturing of oral and sterile cephalosporin products. Its oral cephalosporins include cefixime, cefurozime axetil crystalline, cefuroxime axetil amorphous, cedpodoxime proxetil, cefprozil and cefdinir. Its sterile cephalosporins include cefotaxime sodium, ceftriaxone sodium, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate and cefepime arginine. Its capacities include cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium and ceftriaxone sodium. The Company offers contract manufacturing capabilities for solid dosage forms, such as tablets, capsules, dry powder oral suspension and granules and injectable for cephalosporins.
Employees
1,786
Date Price Change Volume
26-08-14 ₹11.00 -3.00% 315,029
26-08-13 ₹11.34 +5.00% 296,065
26-08-12 ₹10.80 +2.86% 169,332
26-08-11 ₹10.50 +0.10% 242,392
26-08-10 ₹10.49 -0.85% 90,337
  1. Stock Market
  2. Stocks
  3. NECLIFE Stock